Circular RNA: Could this emerging technology trump mRNA?

Circular RNA: Could this emerging technology trump mRNA?

This issue of our newsletter is supported by Global Bio-India 2024.

Circular RNA is an emerging technology that holds a lot of promise for next-generation vaccines.

In fact, scientists believe that it could even be superior to mRNA technology. 

This is thanks to circular RNA’s superior durability, reduced immunogenicity, and potential for cost-effective manufacturing. 

Plus, it could also hold promise for the development of gene therapies. 

So, with several companies – such as Circio and Orna Therapeutics - now joining the circular RNA field, when could the technology enter the clinic?

To find out more, read the full article: The therapeutic potential of circular RNA: Could it soon trump mRNA technology?


A MESSAGE FROM OUR SPONSOR GLOBAL BIO-INDIA 2024

Join us at Global Bio-India 2024: September 12-14 in New Delhi

Be a part of the Global Bio-India 2024, a mega international congregation of biotechnology stakeholders organized by the Dept. of Biotechnology, Govt. of India along with Biotechnology Industry Research Assistance Council (BIRAC) from September 12-14 in New Delhi with a focus on ‘Biotech Innovation Ecosystem’ and ‘Bio-manufacturing’.

👉 Register now


🔥 More noteworthy articles from this week:

It’s summertime, so what could be better than curling up in bed, under a shady tree, or by the pool, and reading a good book? We have curated a list of some of the best biotech books that are bound to get you hooked. From science fiction thrillers to eye-opening discoveries to ones that would make you go, ‘Now that was a real thinker,’ we’ve got you covered.

French biopharma Ipsen has lost a court case against U.S. regulators to have its cancer medication Somatuline Depot regarded as a ‘biologic’ instead of a ‘drug.’ The drugmaker had sued the FDA, after which the regulators won in the District Court for the District of Columbia last year. Now, the appeals court has also sided with the FDA and this decision could have broader implications for the industry.

Epic Bio is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. In this episode, we discussed epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions, with Epic Bio’s founder, Dr Stanley Qi, one of the original inventors of CRISPR.

With single-gene based drug target identification methods getting saturated, the scientific world is venturing beyond traditional approaches to enhance early drug discovery. We explore how combining multi-disciplinary cutting-edge tools, including multivariate analysis, can help in identifying multi-gene targets and improve patient outcomes through precision medicine.


💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.

To view or add a comment, sign in

Explore topics